Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.850
+0.090 (3.26%)
At close: Sep 24, 2026, 4:00 PM EDT
2.810
-0.040 (-1.40%)
After-hours: Sep 24, 2026, 6:05 PM EDT
Nkarta Employees
Nkarta had 106 employees as of June 30, 2026. The number of employees decreased by 4 or -3.64% compared to the same quarter last year.
Employees
106
Change
-4
Growth
-3.64%
Revenue / Employee
n/a
Profits / Employee
-$1,106,830
Market Cap
204.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 106 | -4 | -3.64% |
| Mar 31, 2026 | 108 | -1 | -0.92% |
| Dec 31, 2025 | 108 | -49 | -31.21% |
| Sep 30, 2025 | 105 | -54 | -33.96% |
| Jun 30, 2025 | 110 | -40 | -26.67% |
| Mar 31, 2025 | 109 | -41 | -27.33% |
| Dec 31, 2024 | 157 | 7 | 4.67% |
| Sep 30, 2024 | 159 | -8 | -4.79% |
| Jun 30, 2024 | 150 | -19 | -11.24% |
| Mar 31, 2024 | 150 | -15 | -9.09% |
| Dec 31, 2023 | 150 | -13 | -7.98% |
| Sep 30, 2023 | 167 | 21 | 14.38% |
| Jun 30, 2023 | 169 | 42 | 33.07% |
| Mar 31, 2023 | 165 | 30 | 22.22% |
| Dec 31, 2022 | 163 | 27 | 19.85% |
| Sep 30, 2022 | 146 | 13 | 9.77% |
| Jun 30, 2022 | 127 | 11 | 9.48% |
| Mar 31, 2022 | 135 | 28 | 26.17% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 144 |
| Adagene | 128 |
| PepGen | 57 |
| ALX Oncology Holdings | 48 |
| Protara Therapeutics | 46 |
| Surrozen | 44 |
| Compass Therapeutics | 39 |
| Sol-Gel Technologies | 28 |
NKTX News
- 1 day ago - Nkarta Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 8 days ago - Nkarta Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 14 days ago - Nkarta to Participate in September Investor Conferences - GlobeNewsWire
- 16 days ago - Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 - GlobeNewsWire
- 5 weeks ago - Nkarta price target lowered to $10 from $11 at Stifel - TheFly
- 6 weeks ago - Nkarta price target lowered to $14 from $16 at H.C. Wainwright - TheFly
- 6 weeks ago - Nkarta reports Q2 EPS (54c), consensus (36c) - TheFly
- 6 weeks ago - Nkarta Earnings release: Q2 2026 - Filings